{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:21:32Z","timestamp":1792516892892,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-20-CE26-0007-01"],"award-info":[{"award-number":["ANR-20-CE26-0007-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcyt.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:47:38Z","timestamp":1750387658000},"page":"1262-1269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mapping the European landscape and specificity of ATMPs guidance"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-2143","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Mahalatchimy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Roby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-9184","authenticated-orcid":false,"given":"Julie","family":"V\u00e9ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.06.008_bib0001","unstructured":"Mahalatchimy A. [The impact of EU law on the regulation of advanced therapy medicinal products in France and in the UK], PhD thesis in law, University of Toulouse, France, 2015."},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.008_bib0002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1377\/hlthaff.2014.1023","article-title":"The evolution of biotechnology and its impact on health care","volume":"34","author":"Evens","year":"2015","journal-title":"Health Affairs"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0003","unstructured":"EMA, CAT, CAT quarterly highlights and approved ATMPs\u2014November 2024, EMA\/CAT\/511673\/2024, pp. 3-4."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s43441-025-00769-z","article-title":"Beyond reimbursement status: availability of advanced therapy medicinal products across the European Union","author":"\u010cechov\u00e1","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0005","article-title":"EU soft law in the EU legal order: a literature review","author":"Oana Andreea","year":"2019","journal-title":"King's College London Law School Research Paper Forthcoming"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0006","unstructured":"EMA, Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework, 18 March 2009, EMEA\/P\/24143\/2004 Rev. 1 corr, p. 5."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0007","unstructured":"Mainly Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, OJ L 311, 28.11.2001, pp. 67\u2013128, CELEX number: 32001L0083, and its amendments."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0008","unstructured":"CPMP, Note for guidance on gene therapy product quality aspects in the production of vectors and genetically modified somatic cells, 3AB6a, December 1994."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0009","doi-asserted-by":"crossref","unstructured":"EMA, Guidelines relevant for advanced therapy medicinal products, https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\/guidelines-relevant-advanced-therapy-medicinal-products (last accessed, June 6, 2025). It should be noted that this page lists ATMPs\u2019 scientific guidelines only despite its general title on \u201cGuidelines relevant for advanced therapy medicinal products,\u201d although it provides a link to regulatory and procedural guidance in general (i.e., not specific to ATMPs).","DOI":"10.1093\/law-oeeul\/e230.013.230"},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.008_bib0010","first-page":"389","article-title":"Tissue engineered technologies: regulatory pharmaceuticalization in the European Union","volume":"25","author":"Faulkner","year":"2012","journal-title":"Innovation: The European Journal of Social Science Research"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0011","article-title":"Advanced therapy medicinal products' translation in Europe: a developers","volume":"9","author":"Pizevska","year":"2022","journal-title":"perspective. Front. Med."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0012","unstructured":"\u201cThe following shall be considered as biological medicinal products: immunological medicinal products and medicinal products derived from human blood and human plasma as defined, respectively in paragraphs (4) and (10) of Article 1; medicinal products falling within the scope of Part A of the Annex to Regulation (EEC) No 2309\/93; advanced therapy medicinal products as defined in Part IV of this Annex.\u201d Annex I Part 1, 3.2.1.1b) consolidated Directive 2001\/83\/EC, op.cit."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0013","unstructured":"Regulation (EC) No 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1\u201333, CELEX number: 32004R0726."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0014","unstructured":"According to the EMA, a Biosimilar medicine is \u201cA medicine that is similar to a biological medicine that has already been authorised\u201d: https:\/\/www.ema.europa.eu\/en\/glossary\/biosimilar-medicine (last accessed, June 6, 2025)."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0015","unstructured":"EMA, CPMP, Points to consider concerning endpoints in clinical studies with haematopoietic growth factors for mobilisation of autologous stem cells, CPMP\/EWP\/197\/99, 17 February 2000."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0016","unstructured":"EMA, CHMP, Guideline on potency testing of cell-based immunotherapy medicinal products for the treatment of cancer, EMA\/CHMP\/BWP\/271475\/2006 rev.1, 21 July 2016."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0017","unstructured":"CPMP, Note for guidance on gene therapy product quality aspects in the production of vectors and genetically modified somatic cells, 3AB6a, December 1994."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0018","unstructured":"EMA, CHMP, ICH Guideline S12 on nonclinical biodistribution considerations for gene therapy products \u2014 Step 5, EMA\/CHMP\/ICH\/318372\/2021, 8 September 2023."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0019","unstructured":"EMA, CPMP, Tests on samples of biological origin, 3AB11a, July 1990."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0020","unstructured":"EMA, CHMP, ICH Guideline Q9 (R1) on quality risk management \u2014 Step 5, EMA\/CHMP\/ICH\/24235\/2006, 3 February 2023."},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.008_bib0021","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12916-024-03690-8","article-title":"Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review","volume":"22","author":"Jeffers","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0022","series-title":"Regulatory Aspects of Gene Therapy and Cell Therapy Products. Advances in Experimental Medicine and Biology, vol 1430","article-title":"Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe","author":"Schuessler-Lenz","year":"2023"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0023","unstructured":"Commission Directive 2003\/63\/EC of 25 June 2003 amending Directive 2001\/83\/EC of the European Parliament and of the Council on the Community Code Relating to Medicinal Products for Human Use, OJ L 159, 27.6.2003, pp. 46\u201394."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12032-025-02783-5","article-title":"Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices","volume":"4","author":"Kamli","year":"2025","journal-title":"Med Oncol"},{"issue":"13","key":"10.1016\/j.jcyt.2025.06.008_bib0025","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.3390\/ijms23137167","article-title":"MicroRNA-based diagnosis and therapy","volume":"23","author":"Ho","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.008_bib0026","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"S. Cells"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.01.017","article-title":"The current state of cytotherapy and the field of cell and gene therapy","author":"Hwang","year":"2025","journal-title":"Cytotherapy."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0028","series-title":"2023 EU industrial R&D investment scoreboard","first-page":"50","author":"Nindl","year":"2023"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0029","series-title":"Regulatory Aspects of Gene Therapy and Cell Therapy Products. Advances in Experimental Medicine and Biology, vol 871","article-title":"Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA\/CAT Perspective","author":"Salmikangas","year":"2015"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0030","series-title":"The Oxford Encyclopedia of EU Law [OEEUL]","article-title":"Advanced Therapy Medicinal Products","author":"Fausch","year":"2025"},{"issue":"10S","key":"10.1016\/j.jcyt.2025.06.008_bib0031","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.bulcan.2021.07.002","article-title":"DESCAR-T, le registre national des patients trait\u00e9s par CAR-T Cells [DESCAR-T, a nationwide registry for patients treated by CAR-T Cells in France]","volume":"108","author":"Broussais","year":"2021","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101557","article-title":"Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies","volume":"37","author":"Chabannon","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0033","unstructured":"ICH, 30th Anniversary publication\u2014ICH\u2014the global platform for harmonisation, 2022: https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/ICH30thAnniversaryPublication_2022_0318.pdf (last accessed, June 6, 2025)."},{"key":"10.1016\/j.jcyt.2025.06.008_bib0034","unstructured":"EMA website, The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)\u2014EMA Role. https:\/\/www.ema.europa.eu\/en\/partners-networks\/international-activities\/multilateral-coalitions-initiatives\/international-council-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich (last accessed, June 6th, 2025)."},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.008_bib0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/20508840.2022.2033942","article-title":"Persuasive rather than \u2018binding\u2019 EU soft law? An argumentative perspective on the European Commission\u2019s soft law instruments in times of crisis","volume":"10","author":"Andone","year":"2022","journal-title":"The Theory and Practice of Legislation"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0036","article-title":"Specific guidelines requirements for clinical trials with Advanced Therapy Medicinal Products in the European Union","author":"Mahalatchimy","year":"2022","journal-title":"European Society for Gene & Cell Therapy Congress"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0037","series-title":"Conference on Changing the Face of Modern Medicine\u2014Stem Cell and Gene Therapy, Oct 16-19","article-title":"Update on new ATMP guidelines for GMP production: focus on the risk based approach","author":"Reischl","year":"2018"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.008_bib0038","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ejhpharm-2023-004062","article-title":"European Association of Hospital Pharmacists (EAHP) guidance on the pharmacy handling of in vivo gene therapy medicinal products","volume":"31","author":"J","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1400347","article-title":"The issue of heterogeneity of MSC-based advanced therapy medicinal products\u2014a review","volume":"12","author":"\u010cesnik","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.008_bib0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jcyt.2021.12.004","article-title":"A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies","volume":"24","author":"Capelli","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0041","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41467-024-47866-5","article-title":"A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID","volume":"15","author":"Cesana","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0042","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10561-014-9474-5","article-title":"A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing","volume":"16","author":"Klarmann","year":"2015","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0043","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-031-30040-0_10","article-title":"From the integrity of potency assays to safe clinical intervention: legal perspectives","volume":"1420","author":"Roslin","year":"2023","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.008_bib0044","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.xphs.2023.08.001","article-title":"Cell therapy drug product development: technical considerations and challenges","volume":"112","author":"Weng","year":"2023","journal-title":"Pharm Sci"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2025.108612","article-title":"Advanced therapy medicinal products development\u2014from guidelines to medicines in the market","volume":"83","author":"Frederico","year":"2025","journal-title":"Biotechnol Adv"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.008_bib0046","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/17460751.1.5.709","article-title":"Regulation of tissue-engineered products in the European Union: where are we heading?","volume":"1","author":"Br\u00e9vignon-Dodin","year":"2006","journal-title":"Regen Med"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0047","unstructured":"EMA, CAT, CAT quarterly highlights and approved ATMPs\u2014May 2025, EMA\/CAT\/\/174611\/2025, pp. 4-5. https:\/\/www.ema.europa.eu\/en\/documents\/committee-report\/cat-quarterly-highlights-approved-atmps-may-2025_en.pdf (last accessed, June 6, 2025)."},{"issue":"3","key":"10.1016\/j.jcyt.2025.06.008_bib0048","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcyt.2024.10.004","article-title":"Particulates in CGT guidance survey results\u2014an ISCT process development & manufacturing committee perspective on cell and gene therapy industry knowledge awareness","volume":"27","author":"Durand","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.008_bib0049","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.omtm.2020.05.035","article-title":"Mitigating deficiencies in evidence during regulatory assessments of advanced therapies: a comparative study with other biologicals","volume":"18","author":"Elsallab","year":"2020","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:01:39Z","timestamp":1778943699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925007479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1465324925007479"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.008","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the European landscape and specificity of ATMPs guidance","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}